Literature DB >> 22193048

The value of simultaneous measurements of urinary albumin and total protein in proteinuric patients.

Edward R Smith1, Michael M X Cai, Lawrence P McMahon, David A Wright, Stephen G Holt.   

Abstract

BACKGROUND: Proteinuria is a common pathological finding in renal disease. Examining the urinary protein electrophoretic pattern gives clues to the site of origin of the protein. We hypothesized that the type of proteinuria, classified by urine protein electrophoresis and immunofixation (uPEI), may be predicted by simply examining the proportion of higher molecular weight protein (e.g. albumin) in urine total protein content.
METHODS: One thousand and eleven patients, whose urine had been sent to the pathology department for uPEI, were analysed for total protein and albumin to creatinine ratio (uPCR and uACR) and the ratio reported as the albumin to total protein ratio (uAPR). In a group of renal outpatients (n=248), we also specifically measured tubular proteins (N-acetyl-β-D-glucosaminidase, NAG, and β2-microglobulin) and expressed these as ratios to creatinine (uNCR and uβ2CR). To validate these findings, we correlated these measurements with 68 patients in whom we also had renal biopsy data.
RESULTS: In receiver operating characteristic (ROC) curve analysis, the AUC for uAPR was 0.84 for predicting tubular proteinuria pattern on uPEI. In the renal outpatient subgroup, uAPR predicted a tubular pattern of urinary protein equally as well as testing for specific tubular protein markers (uNCR and uβ2CR). In the validation cohort, a uAPR cut-off of <0.40 was 88% sensitive and 99% specific for the diagnosis of primary tubulointerstitial disorders on renal biopsy.
CONCLUSIONS: Useful information about the origins of urinary protein may be inferred by measuring uAPR, the measurement of which is both simple and inexpensive.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22193048     DOI: 10.1093/ndt/gfr708

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  30 in total

Review 1.  Differential diagnosis of glomerular disease: a systematic and inclusive approach.

Authors:  Lee A Hebert; Samir Parikh; Jason Prosek; Tibor Nadasdy; Brad H Rovin
Journal:  Am J Nephrol       Date:  2013-09-13       Impact factor: 3.754

2.  Longitudinal Assessment of Proximal Tubular Dysfunction in HIV Seropositive and Seronegative Persons: Correlates and Implications.

Authors:  Kerry M Sheets; Mohamed G Atta; Derek M Fine; Katie Zook; Allison M Mcfall; Michelle M Estrella; George J Schwartz; Gregory M Lucas
Journal:  J Acquir Immune Defic Syndr       Date:  2017-05-01       Impact factor: 3.731

3.  Estimating Urine Albumin-to-Creatinine Ratio from Protein-to-Creatinine Ratio: Development of Equations using Same-Day Measurements.

Authors:  Robert G Weaver; Matthew T James; Pietro Ravani; Colin G W Weaver; Edmund J Lamb; Marcello Tonelli; Braden J Manns; Robert R Quinn; Min Jun; Brenda R Hemmelgarn
Journal:  J Am Soc Nephrol       Date:  2020-02-05       Impact factor: 10.121

4.  Proteinuria is associated with neurocognitive impairment in antiretroviral therapy treated HIV-infected individuals.

Authors:  Robert C Kalayjian; Kunling Wu; Scott Evans; David B Clifford; Muraldihar Pallaki; Judith S Currier; Marlene Smryzynski
Journal:  J Acquir Immune Defic Syndr       Date:  2014-09-01       Impact factor: 3.731

5.  Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.

Authors:  Gregory M Lucas; Michael J Ross; Peter G Stock; Michael G Shlipak; Christina M Wyatt; Samir K Gupta; Mohamed G Atta; Kara K Wools-Kaloustian; Paul A Pham; Leslie A Bruggeman; Jeffrey L Lennox; Patricio E Ray; Robert C Kalayjian
Journal:  Clin Infect Dis       Date:  2014-09-17       Impact factor: 9.079

6.  Albuminuria, Proteinuria, and Renal Disease Progression in Children with CKD.

Authors:  Dana Y Fuhrman; Michael F Schneider; Katherine M Dell; Tom D Blydt-Hansen; Robert Mak; Jeffrey M Saland; Susan L Furth; Bradley A Warady; Marva M Moxey-Mims; George J Schwartz
Journal:  Clin J Am Soc Nephrol       Date:  2017-05-25       Impact factor: 8.237

7.  Angiotensin II Type 2-Receptor Agonist C21 Reduces Proteinuria and Oxidative Stress in Kidney of High-Salt-Fed Obese Zucker Rats.

Authors:  Sanket N Patel; Quaisar Ali; Tahir Hussain
Journal:  Hypertension       Date:  2016-03-28       Impact factor: 10.190

8.  The role of albuminuria in the follow-up of HIV-infected pediatric patients.

Authors:  Angela Deyà-Martínez; Antoni Noguera-Julian; Jordi Vila; Anna Vila; Anna Valls; Emília Sánchez; Rafael Jiménez; Clàudia Fortuny
Journal:  Pediatr Nephrol       Date:  2014-04-16       Impact factor: 3.714

9.  Human C-terminal CUBN variants associate with chronic proteinuria and normal renal function.

Authors:  Mathilda Bedin; Olivia Boyer; Aude Servais; Yong Li; Laure Villoing-Gaudé; Marie-Josephe Tête; Alexandra Cambier; Julien Hogan; Veronique Baudouin; Saoussen Krid; Albert Bensman; Florie Lammens; Ferielle Louillet; Bruno Ranchin; Cecile Vigneau; Iseline Bouteau; Corinne Isnard-Bagnis; Christoph J Mache; Tobias Schäfer; Lars Pape; Markus Gödel; Tobias B Huber; Marcus Benz; Günter Klaus; Matthias Hansen; Kay Latta; Olivier Gribouval; Vincent Morinière; Carole Tournant; Maik Grohmann; Elisa Kuhn; Timo Wagner; Christine Bole-Feysot; Fabienne Jabot-Hanin; Patrick Nitschké; Tarunveer S Ahluwalia; Anna Köttgen; Christian Brix Folsted Andersen; Carsten Bergmann; Corinne Antignac; Matias Simons
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

Review 10.  A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection.

Authors:  Stephen G Holt; David M Gracey; Miriam T Levy; David W Mudge; Ashley B Irish; Rowan G Walker; Richard Baer; Jacob Sevastos; Riaz Abbas; Mark A Boyd
Journal:  AIDS Res Ther       Date:  2014-11-10       Impact factor: 2.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.